Keith Speights

Keith Speights

TMFFishBiz

Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries.

Recent articles



5 Biggest Blockbuster Drugs of the Future

Each of these drugs is forecast to rake in at least $9.5 billion in 2024. Investors looking to profit should pay attention to the pharmaceutical giants that sell them.




HEXO's Revenue Soars, but Capacity Limits Its Growth

The Canadian cannabis producer delivered sizzling year-over-year revenue growth in its third quarter thanks to adult-use sales. However, its limited production capacity remained an issue.